Blue Earth Diagnostics (Bracco)

Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.

Blue Earth Diagnostics, based in Oxford and a subsidiary of Bracco, makes the PET imaging agents Posluma, or flotufolastat F-18, also written 18F-rhPSMA-7.3, and Axumin, or fluciclovine F-18, for prostate cancer. Posluma was approved in 2023 on the LIGHTHOUSE and SPOTLIGHT trials, and a therapeutic rhPSMA analogue is in development, which would extend the radiohybrid platform from imaging into treatment. Nuclide links it to prostate cancer and to both tracer records. Whether a fluorine-18 PSMA agent with a matched therapeutic can win share from the gallium-68 tracers already established is the open question. Flotufolastat and fluciclovine have their own pages.

Headquarters

Oxford, GB

Scorecard

All companies

#21of 90 companies, score 33

approved products +12
targets +2
modalities +2
regions +4
registry trials +13

2 approved, 0 in phase 3, 0 earlier, 1 targets, 41 registry studies. Formula on the about page.

Type

radiopharma

Website

www.blueearthdiagnostics.com

Products

2top

ApprovedPET imaging agent

Flotufolastat F-18 · Posluma

Flotufolastat is a third PSMA PET tracer, with a radiohybrid chemistry designed to be reused for therapy.

ApprovedPET radiotracer (synthetic amino acid)

Fluciclovine F-18 · Axumin

Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET.